Industrial - Pollution & Treatment Controls
Compare Stocks
5 / 10Stock Comparison
VLTO vs DHR vs WAT vs TMO vs A
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Medical - Diagnostics & Research
VLTO vs DHR vs WAT vs TMO vs A — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Industrial - Pollution & Treatment Controls | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $22.11B | $124.33B | $22.83B | $176.36B | $33.58B |
| Revenue (TTM) | $5.59B | $24.78B | $3.77B | $45.20B | $7.07B |
| Net Income (TTM) | $969M | $3.69B | $449M | $6.86B | $1.29B |
| Gross Margin | 59.9% | 60.7% | 55.0% | 39.4% | 38.8% |
| Operating Margin | 23.1% | 21.0% | 17.1% | 17.8% | 20.6% |
| Forward P/E | 20.9x | 20.8x | 24.4x | 19.1x | 19.9x |
| Total Debt | $2.67B | $18.42B | $1.41B | $40.85B | $3.35B |
| Cash & Equiv. | $2.03B | $4.62B | $588M | $9.86B | $1.79B |
VLTO vs DHR vs WAT vs TMO vs A — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 23 | May 26 | Return |
|---|---|---|---|
| Veralto Corporation (VLTO) | 100 | 104.9 | +4.9% |
| Danaher Corporation (DHR) | 100 | 79.9 | -20.1% |
| Waters Corporation (WAT) | 100 | 127.7 | +27.7% |
| Thermo Fisher Scien… (TMO) | 100 | 93.8 | -6.2% |
| Agilent Technologie… (A) | 100 | 106.1 | +6.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VLTO vs DHR vs WAT vs TMO vs A
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VLTO has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 6.0%, EPS growth 12.6%, 3Y rev CAGR 4.2%
- Beta 0.66 vs A's 1.23
- 12.9% ROA vs DHR's 4.5%, ROIC 25.7% vs 5.9%
DHR is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.94, Low D/E 35.1%, current ratio 1.87x
WAT is the clearest fit if your priority is growth.
- 7.0% revenue growth vs DHR's 2.9%
TMO is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 229.1% 10Y total return vs DHR's 219.3%
- Lower P/E (19.1x vs 24.4x)
- +16.8% vs DHR's -8.3%
A ranks third and is worth considering specifically for income & stability and valuation efficiency.
- Dividend streak 10 yrs, beta 1.23, yield 0.8%
- PEG 1.35 vs DHR's 34.35
- Beta 1.23, yield 0.8%, current ratio 1.96x
- 18.3% margin vs WAT's 11.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.0% revenue growth vs DHR's 2.9% | |
| Value | Lower P/E (19.1x vs 24.4x) | |
| Quality / Margins | 18.3% margin vs WAT's 11.9% | |
| Stability / Safety | Beta 0.66 vs A's 1.23 | |
| Dividends | 0.8% yield, 10-year raise streak, vs TMO's 0.4%, (1 stock pays no dividend) | |
| Momentum (1Y) | +16.8% vs DHR's -8.3% | |
| Efficiency (ROA) | 12.9% ROA vs DHR's 4.5%, ROIC 25.7% vs 5.9% |
VLTO vs DHR vs WAT vs TMO vs A — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
VLTO vs DHR vs WAT vs TMO vs A — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
VLTO leads in 2 of 6 categories
WAT leads 1 • A leads 1 • DHR leads 0 • TMO leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — VLTO and DHR each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 12.0x WAT's $3.8B. A is the more profitable business, keeping 18.3% of every revenue dollar as net income compared to WAT's 11.9%. On growth, WAT holds the edge at +91.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $5.6B | $24.8B | $3.8B | $45.2B | $7.1B |
| EBITDAEarnings before interest/tax | $1.4B | $7.2B | $953M | $10.5B | $1.7B |
| Net IncomeAfter-tax profit | $969M | $3.7B | $449M | $6.9B | $1.3B |
| Free Cash FlowCash after capex | $1.0B | $5.3B | $264M | $6.7B | $993M |
| Gross MarginGross profit ÷ Revenue | +59.9% | +60.7% | +55.0% | +39.4% | +38.8% |
| Operating MarginEBIT ÷ Revenue | +23.1% | +21.0% | +17.1% | +17.8% | +20.6% |
| Net MarginNet income ÷ Revenue | +17.3% | +14.9% | +11.9% | +15.2% | +18.3% |
| FCF MarginFCF ÷ Revenue | +18.6% | +21.4% | +7.0% | +14.9% | +14.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.8% | +3.7% | +91.5% | +6.2% | +7.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +13.3% | +9.8% | -142.9% | +11.3% | -3.6% |
Valuation Metrics
VLTO leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 23.6x trailing earnings, VLTO trades at a 32% valuation discount to DHR's 34.9x P/E. Adjusting for growth (PEG ratio), A offers better value at 1.76x vs DHR's 34.35x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $22.1B | $124.3B | $22.8B | $176.4B | $33.6B |
| Enterprise ValueMkt cap + debt − cash | $22.8B | $138.1B | $23.7B | $207.4B | $35.1B |
| Trailing P/EPrice ÷ TTM EPS | 23.60x | 34.85x | 32.55x | 26.75x | 25.96x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.94x | 20.82x | 24.36x | 19.11x | 19.87x |
| PEG RatioP/E ÷ EPS growth rate | — | 34.35x | 6.29x | 12.67x | 1.76x |
| EV / EBITDAEnterprise value multiple | 16.79x | 18.21x | 21.51x | 19.04x | 19.89x |
| Price / SalesMarket cap ÷ Revenue | 4.02x | 5.06x | 7.21x | 3.96x | 4.83x |
| Price / BookPrice ÷ Book value/share | 7.15x | 2.38x | 8.17x | 3.34x | 5.00x |
| Price / FCFMarket cap ÷ FCF | 21.81x | 23.64x | 42.30x | 28.02x | 29.15x |
Profitability & Efficiency
VLTO leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
VLTO delivers a 33.4% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $7 for DHR. DHR carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to VLTO's 0.86x. On the Piotroski fundamental quality scale (0–9), DHR scores 7/9 vs WAT's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +33.4% | +7.1% | +8.0% | +13.2% | +18.7% |
| ROA (TTM)Return on assets | +12.9% | +4.5% | +4.6% | +6.4% | +10.1% |
| ROICReturn on invested capital | +25.7% | +5.9% | +20.3% | +7.5% | +13.5% |
| ROCEReturn on capital employed | +23.7% | +7.0% | +18.5% | +9.1% | +14.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 4 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.86x | 0.35x | 0.55x | 0.76x | 0.50x |
| Net DebtTotal debt minus cash | $642M | $13.8B | $820M | $31.0B | $1.6B |
| Cash & Equiv.Liquid assets | $2.0B | $4.6B | $588M | $9.9B | $1.8B |
| Total DebtShort + long-term debt | $2.7B | $18.4B | $1.4B | $40.9B | $3.4B |
| Interest CoverageEBIT ÷ Interest expense | 13.96x | 18.13x | 6.72x | 5.89x | 19.53x |
Total Returns (Dividends Reinvested)
WAT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VLTO five years ago would be worth $11,141 today (with dividends reinvested), compared to $7,893 for DHR. Over the past 12 months, TMO leads with a +16.8% total return vs DHR's -8.3%. The 3-year compound annual growth rate (CAGR) favors WAT at 5.7% vs DHR's -5.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.8% | -23.6% | -8.3% | -19.8% | -13.6% |
| 1-Year ReturnPast 12 months | -7.1% | -8.3% | +1.4% | +16.8% | +11.3% |
| 3-Year ReturnCumulative with dividends | +11.4% | -15.5% | +18.1% | -11.7% | -8.2% |
| 5-Year ReturnCumulative with dividends | +11.4% | -21.1% | +11.3% | +2.8% | -8.0% |
| 10-Year ReturnCumulative with dividends | +11.4% | +219.3% | +162.0% | +229.1% | +205.7% |
| CAGR (3Y)Annualised 3-year return | +3.7% | -5.5% | +5.7% | -4.0% | -2.8% |
Risk & Volatility
Evenly matched — VLTO and WAT each lead in 1 of 2 comparable metrics.
Risk & Volatility
VLTO is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than A's 1.23 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. WAT currently trades 84.6% from its 52-week high vs DHR's 72.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.66x | 0.94x | 1.07x | 1.10x | 1.23x |
| 52-Week HighHighest price in past year | $110.11 | $242.80 | $414.15 | $643.99 | $160.27 |
| 52-Week LowLowest price in past year | $84.99 | $172.06 | $275.05 | $385.46 | $104.79 |
| % of 52W HighCurrent price vs 52-week peak | +80.6% | +72.3% | +84.6% | +73.7% | +74.0% |
| RSI (14)Momentum oscillator 0–100 | 41.8 | 33.0 | 64.9 | 43.1 | 52.5 |
| Avg Volume (50D)Average daily shares traded | 1.7M | 4.2M | 999K | 1.9M | 2.0M |
Analyst Outlook
A leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: VLTO as "Hold", DHR as "Buy", WAT as "Hold", TMO as "Buy", A as "Buy". Consensus price targets imply 40.6% upside for DHR (target: $247) vs 14.9% for WAT (target: $403). For income investors, A offers the higher dividend yield at 0.84% vs TMO's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $106.14 | $247.00 | $402.57 | $654.67 | $166.00 |
| # AnalystsCovering analysts | 12 | 42 | 34 | 42 | 38 |
| Dividend YieldAnnual dividend ÷ price | +0.5% | +0.7% | — | +0.4% | +0.8% |
| Dividend StreakConsecutive years of raises | 2 | 1 | 1 | 8 | 10 |
| Dividend / ShareAnnual DPS | $0.44 | $1.23 | — | $1.69 | $0.99 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.5% | +0.1% | +1.7% | +1.3% |
VLTO leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). WAT leads in 1 (Total Returns). 2 tied.
VLTO vs DHR vs WAT vs TMO vs A: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VLTO or DHR or WAT or TMO or A a better buy right now?
For growth investors, Waters Corporation (WAT) is the stronger pick with 7.
0% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). Veralto Corporation (VLTO) offers the better valuation at 23. 6x trailing P/E (20. 9x forward), making it the more compelling value choice. Analysts rate Danaher Corporation (DHR) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VLTO or DHR or WAT or TMO or A?
On trailing P/E, Veralto Corporation (VLTO) is the cheapest at 23.
6x versus Danaher Corporation at 34. 9x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Agilent Technologies, Inc. wins at 1. 35x versus Danaher Corporation's 34. 35x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — VLTO or DHR or WAT or TMO or A?
Over the past 5 years, Veralto Corporation (VLTO) delivered a total return of +11.
4%, compared to -21. 1% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: TMO returned +229. 1% versus VLTO's +11. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VLTO or DHR or WAT or TMO or A?
By beta (market sensitivity over 5 years), Veralto Corporation (VLTO) is the lower-risk stock at 0.
66β versus Agilent Technologies, Inc. 's 1. 23β — meaning A is approximately 87% more volatile than VLTO relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 86% for Veralto Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — VLTO or DHR or WAT or TMO or A?
By revenue growth (latest reported year), Waters Corporation (WAT) is pulling ahead at 7.
0% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: Veralto Corporation grew EPS 12. 6% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, VLTO leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VLTO or DHR or WAT or TMO or A?
Waters Corporation (WAT) is the more profitable company, earning 20.
3% net margin versus 14. 7% for Danaher Corporation — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAT leads at 28. 2% versus 18. 2% for TMO. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VLTO or DHR or WAT or TMO or A more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Agilent Technologies, Inc. (A) is the more undervalued stock at a PEG of 1. 35x versus Danaher Corporation's 34. 35x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 1x forward P/E versus 24. 4x for Waters Corporation — 5. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 40. 6% to $247. 00.
08Which pays a better dividend — VLTO or DHR or WAT or TMO or A?
In this comparison, A (0.
8% yield), DHR (0. 7% yield), VLTO (0. 5% yield), TMO (0. 4% yield) pay a dividend. WAT does not pay a meaningful dividend and should not be held primarily for income.
09Is VLTO or DHR or WAT or TMO or A better for a retirement portfolio?
For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
94), 0. 7% yield, +219. 3% 10Y return). Both have compounded well over 10 years (DHR: +219. 3%, WAT: +162. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VLTO and DHR and WAT and TMO and A?
These companies operate in different sectors (VLTO (Industrials) and DHR (Healthcare) and WAT (Healthcare) and TMO (Healthcare) and A (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
DHR, A pay a dividend while VLTO, WAT, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.